News

Europe's DARWIN EU Data Program Adds Capacity

March 08, 2024

EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Final Analytical Procedures Guidance Published

March 07, 2024

FDA has published final guidance documents regarding validation and development of analytical procedures.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

March 07, 2024

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

Cellares Innovates With Automated Cell and Gene Therapy Platform

March 07, 2024

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

March 06, 2024

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

CordenPharma Expands Clinical Peptide Capacity

March 06, 2024

The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.

Research into Cold Cancers Heating Up

March 04, 2024

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

A New “Voyage”

March 03, 2024

The power of collaboration is a critically important for the bio/pharma industry.

Budget Benefit

March 02, 2024

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.